Leanna R. Staben

Most-cited papers

1. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus

   Sophie M. Lehar, Thomas H. Pillow, Min Xu, Leanna R. Staben +28 more

   2015Nature752 citations

   Semantic Scholar

   Save

2. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.

   P. Dragovich, Thomas H. Pillow, R. Blake, J. Sadowsky +33 more

   2021Journal of Medicinal Chemistry139 citations

   Semantic Scholar

   Save

3. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.

   P. Dragovich, Thomas H. Pillow, R. Blake, J. Sadowsky +33 more

   2021Journal of Medicinal Chemistry119 citations

   Semantic Scholar

   Save

4. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

   Leanna R. Staben, Stefan G. Koenig, Sophie M. Lehar, R. Vandlen +19 more

   2016Nature Chemistry114 citations

   Semantic Scholar

   Save

5. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα).

   P. Dragovich, Pragya Adhikari, R. Blake, N. Blaquiere +39 more

   2019Bioorganic & Medicinal Chemistry Letters103 citations

   Semantic Scholar

   Save

6. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

   Thomas H. Pillow, Janet Y. Tien, K. Parsons-Reponte, Sunil Bhakta +23 more

   2014Journal of Medicinal Chemistry101 citations

   Semantic Scholar

   Save

7. Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.

   Binqing Wei, Janet Gunzner-Toste, Hui Yao, Tao Wang +29 more

   2017Journal of Medicinal Chemistry88 citations

   Semantic Scholar

   Save

8. PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.

   Michael Berlin, J. Cantley, M. Bookbinder, E. Bortolon +37 more

   2024Journal of Medicinal Chemistry34 citations Open access

   Semantic Scholar

   Save

9. Discovery of N-[4-[6-tert-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase

   F. Talamas, Sarah C. Abbot, Shalini Anand, K. Brameld +26 more

   2013Journal of Medicinal Chemistry31 citations Open access

   Semantic Scholar

   Save

10. Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody-Drug Conjugates with Phenol-Containing Payloads.

    Donglu Zhang, Hoa Le, Josefa Dela Cruz-Chuh, Sudheer Bobba +16 more

    2018Bioconjugate chemistry23 citations

    Semantic Scholar

    Save

11. Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.

    Leanna R. Staben, Shang-Fan Yu, Jinhua Chen, Gang Yan +18 more

    2017ACS Medicinal Chemistry Letters23 citations Open access

    Semantic Scholar

    Save

12. Systematic Variation of Pyrrolobenzodiazepine (PBD)-dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.

    Leanna R. Staben, Jinhua Chen, Josefa Dela Cruz-Chuh, Geoffrey Del Rosario +16 more

    2020Journal of Medicinal Chemistry14 citations

    Semantic Scholar

    Save

13. A Novel Depurination Methodology to Assess DNA Alkylation of Chloro-Bis-Seco-Cyclopropylbenzoindoles Allowed for Comparison of Minor-Groove Reactivity

    Shuai Wang, Buyun Chen, P. Dragovich, Thomas H. Pillow +12 more

    2019Drug Metabolism And Disposition4 citations Open access

    Semantic Scholar

    Save

14. Modulation of VHL binding affinity improves selectivity of PROTACs targeting BRM (SMARCA2) over BRG1 (SMARCA4)

    Michael Berlin, Jennifer L. Cantley, Fabio Broccatelli, Lin Cao +24 more

    2026Results in Chemistry0 citations Open access

    Semantic Scholar

    Save

15. Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models".

    Michael Berlin, J. Cantley, M. Bookbinder, E. Bortolon +41 more

    2025Journal of Medicinal Chemistry0 citations

    Semantic Scholar

    Save

16. Abstract 5687: Selective, chemically-induced degradation of BRM (SMARCA2) enablesin vivoefficacy in BRG1 (SMARCA4)-deficient xenograft tumor models

    Michael Berlin, Jennifer L. Cantley, Jing Wang, M. Bookbinder +27 more

    2020Cancer Chemistry0 citations

    Semantic Scholar

    Save